Biotech company Polyrizon has closed a private placement, raising $17 million to support the development of its intranasal hydrogels, which act as a barrier against viruses and allergens. The funds will be used for general corporate purposes and working capital. Aegis Capital Corp. served as the exclusive placement agent for the offering.